CHRM2抗体;CHRM2 Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human fetal brain tissue , Primary antibody: P12719(CHRM2 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 60 seconds    

  
  

The CHRM2 antibody targets the cholinergic muscarinic acetylcholine receptor M2 (CHRM2), a G protein-coupled receptor (GPCR) critical in mediating parasympathetic nervous system responses. CHRM2 is predominantly expressed in the heart, smooth muscles, and specific regions of the central nervous system. It regulates heart rate by slowing sinoatrial node activity, influences smooth muscle contraction, and modulates cognitive functions such as memory and learning. Dysregulation of CHRM2 has been linked to cardiovascular disorders, neurodegenerative diseases, and psychiatric conditions, making it a key focus in pharmacological research.

CHRM2 antibodies are essential tools for studying receptor localization, expression levels, and functional interactions. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to visualize receptor distribution in tissues or cultured cells. Specificity and validation of these antibodies are crucial, often confirmed using CHRM2 knockout models or competitive binding assays. Researchers also employ CHRM2 antibodies to explore receptor signaling pathways, such as Gi/o protein coupling and downstream effectors like adenylate cyclase.

Recent studies highlight CHRM2's role in diseases like atrial fibrillation, Alzheimer's disease, and schizophrenia, driving interest in therapeutic targeting. However, challenges remain in developing selective ligands due to structural similarities among muscarinic receptor subtypes. CHRM2 antibodies thus serve as vital reagents for both basic research and drug discovery efforts.